Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02691351

Enrollment

500

Registered

2016-02-25

Start date

2016-03-31

Completion date

2020-09-30

Last updated

2020-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin T-cell Lymphoma

Brief summary

The better understanding of non-Hodgkin T-cell lymphoma is essential for establishing effective treatment strategy for non-Hodgkin T-cell lymphoma. Therefore, the data about conical features and treatment outcomes of each subtype should be accumulated to establish treatment strategy. However, the majority of previous data for non-Hodgkin T-cell lymphoma was from small case series of single institute. Furthermore, as novel drugs were developed for the treatment of relapsed or refractory T-cell lymphoma, the date from patients who were treated with those novel drugs are especially required because their outcomes may reflect the outcomes of currently available treatments. Thus, a multinational, multicenter prospective registry study is needed to provide information useful for establishing treatment strategies for T-cell lymphoma.

Interventions

OTHERProspective Registry

Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment 1. Regimen 2. Response Evaluation 3. SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pathologically diagnosed Mature T-cell non-Hodgkin lymphoma based on the World Health Organization classification 2008 * Newly diagnosed patients without a previous treatment history for T-cell lymphoma or relapsed/refractory T-cell lymphoma patients * Age ≥19 years * Written informed consent

Exclusion criteria

* Hodgkin lymphoma * non-Hodgkin B-cell lymphoma * Immature non-Hodgkin T-cell lymphoma: Precursor T-lymphoblastic lymphoma/leukemia * Not understanding informed consent

Design outcomes

Primary

Measure	Time frame
Overall survival	5 years

Secondary

Measure	Time frame
Overall response rate to primary treatment and salvage treatment	5 years
Progression-free survival	5 years

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026